ClinicalTrials.gov
ClinicalTrials.gov Menu

Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00115635
Recruitment Status : Completed
First Posted : June 24, 2005
Last Update Posted : October 2, 2007
Sponsor:
Collaborators:
Sanofi
Eli Lilly and Company
Information provided by:
Herlev Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Actual Study Completion Date : July 2007